Literature DB >> 33625616

Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.

Muthukrishnan Chandrika1, Pei Jou Chua1, Umamaheswari Muniasamy1, Ruby Yun Ju Huang2, Aye Aye Thike3, Cheng Teng Ng1, Puay Hoon Tan3, George W Yip4, Boon Huat Bay5.   

Abstract

PURPOSE: Breast cancer is the most common type of cancer affecting women worldwide. Phosphoglycerate dehydrogenase (PHGDH) is an oxidoreductase in the serine biosynthesis pathway. Although it has been reported to affect growth of various tumors, its role in breast cancer is largely unknown. This study aimed to analyze the expression of PHGDH in breast cancer tissue samples and to determine if PHGDH regulates breast cancer cell proliferation.
METHODS: Tissue microarrays consisting of 305 cases of breast invasive ductal carcinoma were used for immunohistochemical evaluation of PHGDH expression. The role of PHGDH in breast cancer was investigated in vitro by knocking down its expression and determining the effect on cell proliferation and cell cycling, and in ovo by using a chorioallantoic membrane (CAM) assay.
RESULTS: Immunohistochemical examination showed that PHGDH is mainly localized in the cytoplasm of breast cancer cells and significantly associated with higher cancer grade, larger tumor size, increased PCNA expression, and lymph node positivity. Analysis of the GOBO dataset of 737 patients demonstrated that increased PHGDH expression was associated with poorer overall survival. Knockdown of PHGDH expression in breast cancer cells in vitro resulted in a decrease in cell proliferation, reduction in cells entering the S phase of the cell cycle, and downregulation of various cell cycle regulatory genes. The volume of breast tumor in an in ovo CAM assay was found to be smaller when PHGDH was silenced.
CONCLUSION: The findings suggest that PHGDH has a regulatory role in breast cancer cell proliferation and may be a potential prognostic marker and therapeutic target in breast cancer.

Entities:  

Keywords:  Biomarker; Breast cancer; Cell cycle; Cell proliferation; Phosphoglycerate dehydrogenase

Mesh:

Substances:

Year:  2021        PMID: 33625616     DOI: 10.1007/s10549-021-06123-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  3 in total

1.  Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.

Authors:  Ying-Nan Yu; George Wai-Cheong Yip; Puay-Hoon Tan; Aye Aye Thike; Ken Matsumoto; Masafumi Tsujimoto; Boon-Huat Bay
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

2.  Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour.

Authors:  Chun-Hua Guo; Chuay-Yeng Koo; Boon-Huat Bay; Puay-Hoon Tan; George W Yip
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

3.  HER2 breast cancer therapies: a review.

Authors:  Conleth G Murphy; Shanu Modi
Journal:  Biologics       Date:  2009-07-13
  3 in total
  2 in total

1.  HBV preS Mutations Promote Hepatocarcinogenesis by Inducing Endoplasmic Reticulum Stress and Upregulating Inflammatory Signaling.

Authors:  Wenbin Liu; Shiliang Cai; Rui Pu; Zixiong Li; Donghong Liu; Xinyu Zhou; Jianhua Yin; Xi Chen; Liping Chen; Jianfeng Wu; Xiaojie Tan; Xin Wang; Guangwen Cao
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

Review 2.  In ovo model in cancer research and tumor immunology.

Authors:  Lea Miebach; Julia Berner; Sander Bekeschus
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.